Cytokinetics, Incorporated

BIT:1CYTK Stock Report

Market Cap: €8.2b

Cytokinetics Valuation

Is 1CYTK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 1CYTK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 1CYTK (€60.9) is trading below our estimate of future cash flow value (€343.27)

Significantly Below Future Cash Flow Value: 1CYTK is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1CYTK?

Key metric: As 1CYTK barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 1CYTK. This is calculated by dividing 1CYTK's market cap by their current book value.
What is 1CYTK's PB Ratio?
PB Ratio-11.5x
Book-US$826.57m
Market CapUS$9.52b

Price to Book Ratio vs Peers

How does 1CYTK's PB Ratio compare to its peers?

The above table shows the PB ratio for 1CYTK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average8.7x
PHIL Philogen
2.4x-107.28%€912.4m
REC Recordati Industria Chimica e Farmaceutica
5x15.27%€10.3b
6446 PharmaEssentia
10.2x46.56%NT$352.7b
ARWR Arrowhead Pharmaceuticals
17.1x28.06%US$10.5b
1CYTK Cytokinetics
n/a51.85%€9.5b

Price-To-Book vs Peers: 1CYTK has negative equity and a Price-To-Book Ratio (-11.5x) compared to the peer average (8.7x).

Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Book Ratio vs Industry

How does 1CYTK's PB Ratio compare vs other companies in the European Biotechs Industry?

30 CompaniesPrice / BookEstimated GrowthMarket Cap
1CYTK is unprofitableIndustry Avg. 2.9xNo. of Companies30PB01.63.24.86.48+
30 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 1CYTK has negative equity and a Price-To-Book Ratio (-11.5x) compared to the European Biotechs industry average (2.9x).

Price to Book Ratio vs Fair Ratio

What is 1CYTK's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1CYTK PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-11.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 1CYTK's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1CYTK forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€60.90
€90.84
+49.16%
15.37%€126.67€59.86n/a20
Jun ’27€63.98
€90.21
+41.00%
15.37%€125.79€59.45n/a20
May ’27€54.30
€79.50
+46.40%
16.20%€115.86€57.08n/a19
Apr ’27€57.50
€79.74
+38.67%
17.25%€117.42€57.85n/a17
Mar ’27€53.00
€77.25
+45.75%
18.07%€115.23€51.69n/a18
Feb ’27€54.50
€75.42
+38.38%
18.35%€114.68€51.44n/a18
Jan ’27€52.00
€73.62
+41.57%
19.20%€115.67€51.88n/a18
Dec ’26€58.00
€67.49
+16.37%
22.60%€103.25€35.28n/a18
Nov ’26€54.50
€65.57
+20.30%
24.64%€103.75€35.45n/a18
Oct ’26€46.40
€63.60
+37.07%
25.68%€102.22€34.92n/a18
Sep ’26€31.40
€60.66
+93.18%
27.14%€102.44€35.00n/a19
Aug ’26€31.80
€62.41
+96.27%
28.48%€103.87€35.49n/a19
Jul ’26€28.60
€62.22
+117.55%
27.71%€102.91€35.16n/a20
Jun ’26€27.40
€64.69
+136.11%
26.69%€105.70€36.11€63.9820
May ’26€37.00
€68.37
+84.78%
23.70%€106.28€41.63€54.3021
Apr ’26n/a
€71.62
0%
21.58%€109.62€42.93€57.5020
Mar ’26n/a
€76.27
0%
20.05%€115.70€57.85€53.0020
Feb ’26n/a
€78.35
0%
19.86%€115.20€57.60€54.5018
Jan ’26n/a
€78.51
0%
20.41%€115.31€57.65€52.0017
Dec ’25n/a
€76.13
0%
20.69%€113.40€56.70€58.0016
Nov ’25n/a
€75.93
0%
21.13%€109.70€54.85€54.5017
Oct ’25n/a
€73.36
0%
18.55%€96.56€54.14€46.4017
Sep ’25n/a
€72.82
0%
19.01%€96.27€53.98€31.4017
Aug ’25n/a
€77.12
0%
16.79%€99.84€55.99€31.8017
Jul ’25n/a
€77.12
0%
16.79%€99.84€55.99€28.6017
Jun ’25n/a
€78.81
0%
18.79%€112.96€55.55€27.4017
€90.89
Fair Value
33.0% undervalued intrinsic discount
20
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/14 13:44
End of Day Share Price 2026/06/12 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cytokinetics, Incorporated is covered by 37 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Carter GouldBarclays
Emily FieldBarclays
Huidong WangBarclays